Ying-lei Gao

发表

Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer.

Hong Liu, M. Zheng, M. Geng, 2017, Journal of medicinal chemistry.

Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.

Yun Tang, Yi Chen, Z. Miao, 2017, European journal of medicinal chemistry.

Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3Kα-selective inhibitor CYH33 in breast cancer.

Yi Chen, Jian Ding, Ling-hua Meng, 2018, Cancer letters.

EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma

Yi Chen, Jian Ding, S. Xie, 2019, Haematologica.

18F-FDG PET as an imaging biomarker for the response to FGFR-targeted therapy of cancer cells via FGFR-initiated mTOR/HK2 axis

Hu Zhou, Ruimin Huang, Yuchen Jiang, 2022, Theranostics.

Discovery of 3-(5'-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological Evaluation.

C. Luo, M. Geng, Fanwang Meng, 2016, Journal of medicinal chemistry.

Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance

Yi Chen, Z. Miao, Jian Ding, 2023, EMBO molecular medicine.

Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors

Yi Chen, Z. Miao, Jian Ding, 2017, Acta Pharmacologica Sinica.

Discovery of a series of dimethoxybenzene FGFR inhibitors with 5H-pyrrolo[2,3-b]pyrazine scaffold: structure–activity relationship, crystal structural characterization and in vivo study

M. Geng, B. Xiong, Jing-kang Shen, 2018, Acta pharmaceutica Sinica. B.

An orally available tyrosine kinase ALK and RET dual inhibitor bearing the tetracyclic benzo[b]carbazolone core.

M. Geng, Yin-chun Ji, L. Xing, 2016, European journal of medicinal chemistry.

Design, synthesis and biological evaluation of HSP90 inhibitor-SN38 conjugates for targeted drug accumulation.

Yan-fen Fang, Wei-Yu Lu, Shulei Zhu, 2020, Journal of medicinal chemistry.

Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against human thyroid cancer

Yi Chen, Jian Ding, M. Geng, 2017, Acta Pharmacologica Sinica.

Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer

Yi Chen, Jian Ding, Linghua Meng, 2019, Cancer biology & medicine.

Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models

Yi Chen, Jian Ding, M. Geng, 2017, Molecular Cancer Therapeutics.

Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma.

M. Geng, B. Xiong, Yuchen Jiang, 2019, European journal of medicinal chemistry.

SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors

Jian Ding, Yan-fen Fang, M. Geng, 2020, Acta pharmacologica Sinica.

SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors

Jian Ding, Yan-fen Fang, M. Geng, 2020, Acta Pharmacologica Sinica.

Dysregulation of iron homeostasis by TfR-1 renders EZH2 wild type diffuse large B-cell lymphoma resistance to EZH2 inhibition

Yi Chen, Yan-fen Fang, Qian-qian Shen, 2023, Acta Pharmacologica Sinica.

Simultaneous inhibition of PI 3 Kα and CDK 4 / 6 synergistically suppresses KRAS-mutated non-small cell lung cancer

Yi Chen, Jian Ding, Linghua Meng, 2019 .

Identification of [1,2,4]Triazolo[4,3-a]pyrazine PARP1 inhibitors with overcome acquired resistance activities.

Yi Chen, Z. Miao, Pingyuan Wang, 2023, European journal of medicinal chemistry.

Degradation of Cyclin-Dependent Kinase 9/Cyclin T1 by Optimized Microtubule-Associated Protein 1 Light Chain 3 Beta-Recruiting Coumarin Analogs.

Youhong Hu, Ying-lei Gao, Yanping Zeng, 2023, Journal of medicinal chemistry.

The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKKα and overcomes gefitinib resistance in non-small cell lung cancer

Yi Chen, Fajun Nan, Jian Ding, 2022, Cancer biology & medicine.